Efficacy and Safety of Tripterygium Glycosides for Graves Ophthalmopathy: A Systematic Review and Meta-analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2019 Dec 20

PMID 31852090

Citations 5

Authors

Xiaowei Liu

Chenghan Gao

Xiaolin Liu

Tianshu Gao

Affiliations

Soon will be listed here.

Abstract

Background: Graves ophthalmopathy (GO) is one of the remaining enigmas in thyroidology. Glucocorticoids (GCs) are strongly recommended but their effects are not completely satisfactory and adverse reactions can occur. Tripterygium glycosides (TG) is a promising component extracted from Tripterygium wilfordii Hook F (TwHF), and numerous patients with GO have benefited from it. However, its practical application value is still unclear. The aim of this systematic review and meta-analysis was to investigate the efficacy and safety of TG for patients with GO.

Methods: By retrieving the PubMed, Embase, the Cochrane Library, CNKI, VIP, CBM, and WanFang Databases, the open published randomized controlled trials (RCTs) related to TG in the treatment of GO were collected. And inclusion and exclusion criteria were established. The Cochrane bias risk assessment tool conducts the evaluation of included studies, and meta-analysis was performed using Revman 5.3 software.

Trial Registration Number: PROSPERO CRD42019131915.

Results: A total of 19 trials (involving 1517 GO patients) were included in this review with generally acceptable validity of included RCTs. TG therapy brought about a significantly higher efficacy rate compared with non-TG treatments (RR: 1.40; 95% CI: 1.31-1.49). Subgroup meta-analysis showed that TG with or without immunosuppressive therapies were all better than controls: with GC (RR: 1.36; 95% CI: 1.27-1.46), with multiple intensification of immunosuppressive therapies (RR: 1.91; 95% CI: 1.37-2.67), with no immunosuppressive therapies (RR: 1.39; 95% CI:1.21-1.59); the dosage of TG for 15-60 mg/d (RR: 1.41; 95% CI: 1.30-1.53) were better compared with for ≥90 mg/d (RR: 1.47; 95% CI: 1.29-1.68); the course of treatment for ≤3 months (RR: 1.43; 95% CI: 1.33-1.52) was better than controls, but when >3 months (RR: 1.15; 95% CI: 0.94-1.41) there was no significant differences. After treatment, the degree of exophthalmus (SMD: -2.55; 95% CI: -2.93 to 2.17), the recurrence rate of 1 year (RR: 0.45; 95% CI: 0.27-0.74), and adverse reactions rate (RR: 0.32; 95% CI: 0.20-0.53) were all lower, while the CAS was no obvious gap in 2 groups (SMD: 0.08; 95% CI: -0.60 to 0.75).

Conclusions: This review found that TG has some advantages in treating GO, especially in improving clinical efficacy and reducing adverse reactions. Nevertheless, large sample, multi-center, reasonable design, and high quality clinical studies are still needed for further verification.

Citing Articles

The efficacy of Tripterygium Glycosides in the treatment of Chinese patients with thyroid-associated orbitopathy: a systematic review and meta-analysis.

Li M, Wei B, Gao T, Gao C Front Pharmacol. 2025; 15():1433791.

PMID: 39834834 PMC: 11743945. DOI: 10.3389/fphar.2024.1433791.

Effect of traditional Chinese medicine on Graves' disease: a network meta-analysis.

Yang Z, Zhao N, Li J, Wu Z, Ma J Front Pharmacol. 2024; 15:1411459.

PMID: 39239642 PMC: 11374712. DOI: 10.3389/fphar.2024.1411459.

Individualized medication based on pharmacogenomics and treatment progress in children with IgAV nephritis.

Yang X, Li Q, He Y, Zhu Y, Yang R, Zhu X Front Pharmacol. 2022; 13:956397.

PMID: 35935867 PMC: 9355498. DOI: 10.3389/fphar.2022.956397.

Mechanism-Based Pharmacokinetic Model for the Deglycosylation Kinetics of 20(S)-Ginsenosides Rh2.

Ren H, Sun J, A J, Gu S, Shi J, Shao F Front Pharmacol. 2022; 13:804377.

PMID: 35694247 PMC: 9175024. DOI: 10.3389/fphar.2022.804377.

New Therapeutic Horizon of Graves' Hyperthyroidism: Treatment Regimens Based on Immunology and Ingredients From Traditional Chinese Medicine.

He Q, Dong H, Gong M, Guo Y, Xia Q, Gong J Front Pharmacol. 2022; 13:862831.

PMID: 35462920 PMC: 9020194. DOI: 10.3389/fphar.2022.862831.

References

Hiromatsu Y, Yang D, Bednarczuk T, Miyake I, Nonaka K, Inoue Y . Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2000; 85(3):1194-9. DOI: 10.1210/jcem.85.3.6433. View

Wang H, Jiang Q, Feng X, Zhang H, Ge L, Luo C . Tripterygium wilfordii Hook F versus conventional synthetic disease-modifying anti-rheumatic drugs as monotherapy for rheumatoid arthritis: a systematic review and network meta-analysis. BMC Complement Altern Med. 2016; 16:215. PMC: 4944439. DOI: 10.1186/s12906-016-1194-x. View

Forster G, Otto E, Hansen C, Ochs K, Kahaly G . Analysis of orbital T cells in thyroid-associated ophthalmopathy. Clin Exp Immunol. 1998; 112(3):427-34. PMC: 1904994. DOI: 10.1046/j.1365-2249.1998.00613.x. View

Zhao Q, Li X, Feng Q, Sun R . [Evaluation on dosage-based efficacy-toxicity correlation of Tripterygium wilfordii against immune inflammation in mice]. Zhongguo Zhong Yao Za Zhi. 2015; 40(6):1139-43. View

Dong Y, Zhang B, Lin Z, Zhang X . [Pharmacodynamic effect and virulent effect of Tripterygium wilfordii based on network pharmacology]. Zhongguo Zhong Yao Za Zhi. 2019; 44(16):3460-3467. DOI: 10.19540/j.cnki.cjcmm.20181119.001. View

Yang Y, Liu Z, Tolosa E, Yang J, Li L . Triptolide induces apoptotic death of T lymphocyte. Immunopharmacology. 1998; 40(2):139-49. DOI: 10.1016/s0162-3109(98)00036-8. View

Li C, Li T, Zhu Z, Xie J, Wei L . [Advance in studies on anti-inflammatory and immunoregulatory monomers of Tripterygium wilfordii]. Zhongguo Zhong Yao Za Zhi. 2015; 39(21):4159-64. View

Yang D, Hiromatsu Y, Hoshino T, Inoue Y, Itoh K, Nonaka K . Dominant infiltration of T(H)1-type CD4+ T cells at the retrobulbar space of patients with thyroid-associated ophthalmopathy. Thyroid. 1999; 9(3):305-10. DOI: 10.1089/thy.1999.9.305. View

Li X, Jiang Z, Zhang L . Triptolide: progress on research in pharmacodynamics and toxicology. J Ethnopharmacol. 2014; 155(1):67-79. DOI: 10.1016/j.jep.2014.06.006. View

10.

Wiersinga W . Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy. Lancet Diabetes Endocrinol. 2016; 5(2):134-142. DOI: 10.1016/S2213-8587(16)30046-8. View

11.

Liu L, Zhao H, Sun X, Zheng Q, Luo Y, Ru Y . Efficacy and safety of Tripterygium wilfordii hook F for chronic urticaria: a systematic review and meta-analysis. BMC Complement Altern Med. 2018; 18(1):243. PMC: 6119305. DOI: 10.1186/s12906-018-2305-7. View

12.

Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly G, Marcocci C . The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. Eur Thyroid J. 2016; 5(1):9-26. PMC: 4836120. DOI: 10.1159/000443828. View

13.

Kusunoki N, Yamazaki R, Kitasato H, Beppu M, Aoki H, Kawai S . Triptolide, an active compound identified in a traditional Chinese herb, induces apoptosis of rheumatoid synovial fibroblasts. BMC Pharmacol. 2004; 4:2. PMC: 373449. DOI: 10.1186/1471-2210-4-2. View

14.

Ponto K, Merkesdal S, Hommel G, Pitz S, Pfeiffer N, Kahaly G . Public health relevance of Graves' orbitopathy. J Clin Endocrinol Metab. 2012; 98(1):145-52. DOI: 10.1210/jc.2012-3119. View

15.

Wang J, Zou X, Wang C, Wang X . [Tripterygium glycosides in treatment of henoch-schonlein purpura nephritis: a systematic review of randomized controlled trials]. Zhongguo Zhong Yao Za Zhi. 2018; 43(13):2806-2816. DOI: 10.19540/j.cnki.cjcmm.20180327.005. View

16.

Gerding M, Terwee C, Dekker F, Koornneef L, Prummel M, Wiersinga W . Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument. Thyroid. 1998; 7(6):885-9. DOI: 10.1089/thy.1997.7.885. View

17.

Tanda M, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L . Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center. J Clin Endocrinol Metab. 2013; 98(4):1443-9. DOI: 10.1210/jc.2012-3873. View

18.

Xu J, Xu C, Chen J, Jin Z, Zheng H, Zhu J . [Peripheral blood cell factors of Graves ophthalmopathy and effect of intervention with tripterygium glycosides]. Zhongguo Zhong Yao Za Zhi. 2014; 39(3):544-7. View

19.

Wang D, Zhao X, Cui Y, Zhang T, Wang F, Hu Y . Efficacy and safety of Tripterygium wilfordii Hook F for CKD in Mainland China: A systematic review and meta-analysis. Phytother Res. 2017; 32(3):436-451. DOI: 10.1002/ptr.5987. View

20.

Aniszewski J, Valyasevi R, Bahn R . Relationship between disease duration and predominant orbital T cell subset in Graves' ophthalmopathy. J Clin Endocrinol Metab. 2000; 85(2):776-80. DOI: 10.1210/jcem.85.2.6333. View